Your browser doesn't support javascript.
loading
Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.
Morgado-Palacin, Isabel; Day, Amanda; Murga, Matilde; Lafarga, Vanesa; Anton, Marta Elena; Tubbs, Anthony; Chen, Hua Tang; Ergan, Aysegul; Anderson, Rhonda; Bhandoola, Avinash; Pike, Kurt G; Barlaam, Bernard; Cadogan, Elaine; Wang, Xi; Pierce, Andrew J; Hubbard, Chad; Armstrong, Scott A; Nussenzweig, André; Fernandez-Capetillo, Oscar.
Afiliación
  • Morgado-Palacin I; Genomic Instability Group; Spanish National Cancer Research Center (CNIO); Madrid 28029, Spain.
  • Day A; Laboratory of Genome Integrity; National Cancer Institute; National Institutes of Health; Bethesda, MD 20892, USA.
  • Murga M; Genomic Instability Group; Spanish National Cancer Research Center (CNIO); Madrid 28029, Spain.
  • Lafarga V; Genomic Instability Group; Spanish National Cancer Research Center (CNIO); Madrid 28029, Spain.
  • Anton ME; Genomic Instability Group; Spanish National Cancer Research Center (CNIO); Madrid 28029, Spain.
  • Tubbs A; Laboratory of Genome Integrity; National Cancer Institute; National Institutes of Health; Bethesda, MD 20892, USA.
  • Chen HT; Laboratory of Genome Integrity; National Cancer Institute; National Institutes of Health; Bethesda, MD 20892, USA.
  • Ergan A; Laboratory of Genome Integrity; National Cancer Institute; National Institutes of Health; Bethesda, MD 20892, USA.
  • Anderson R; Laboratory of Genome Integrity; National Cancer Institute; National Institutes of Health; Bethesda, MD 20892, USA.
  • Bhandoola A; Laboratory of Genome Integrity; National Cancer Institute; National Institutes of Health; Bethesda, MD 20892, USA.
  • Pike KG; AstraZeneca, Cambridge, CB4 0WG, UK.
  • Barlaam B; AstraZeneca, Cambridge, CB4 0WG, UK.
  • Cadogan E; AstraZeneca, Cambridge, CB4 0WG, UK.
  • Wang X; Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
  • Pierce AJ; AstraZeneca, Cambridge, CB4 0WG, UK.
  • Hubbard C; Laboratory of Genome Integrity; National Cancer Institute; National Institutes of Health; Bethesda, MD 20892, USA.
  • Armstrong SA; Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
  • Nussenzweig A; Laboratory of Genome Integrity; National Cancer Institute; National Institutes of Health; Bethesda, MD 20892, USA.
  • Fernandez-Capetillo O; Genomic Instability Group; Spanish National Cancer Research Center (CNIO); Madrid 28029, Spain.
Sci Signal ; 9(445): ra91, 2016 09 13.
Article en En | MEDLINE | ID: mdl-27625305
ABSTRACT
Among the various subtypes of acute myeloid leukemia (AML), those with chromosomal rearrangements of the MLL oncogene (AML-MLL) have a poor prognosis. AML-MLL tumor cells are resistant to current genotoxic therapies because of an attenuated response by p53, a protein that induces cell cycle arrest and apoptosis in response to DNA damage. In addition to chemicals that damage DNA, efforts have focused on targeting DNA repair enzymes as a general chemotherapeutic approach to cancer treatment. Here, we found that inhibition of the kinase ATR, which is the primary sensor of DNA replication stress, induced chromosomal breakage and death of mouse AML(MLL) cells (with an MLL-ENL fusion and a constitutively active N-RAS independently of p53. Moreover, ATR inhibition as a single agent exhibited antitumoral activity, both reducing tumor burden after establishment and preventing tumors from growing, in an immunocompetent allograft mouse model of AML(MLL) and in xenografts of a human AML-MLL cell line. We also found that inhibition of ATM, a kinase that senses DNA double-strand breaks, also promoted the survival of the AML(MLL) mice. Collectively, these data indicated that ATR or ATM inhibition represent potential therapeutic strategies for the treatment of AML, especially MLL-driven leukemias.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_leukemia Asunto principal: Reordenamiento Génico / Leucemia Mieloide Aguda / N-Metiltransferasa de Histona-Lisina / Proteína de la Leucemia Mieloide-Linfoide / Proteínas de la Ataxia Telangiectasia Mutada / Neoplasias Experimentales Límite: Animals / Humans Idioma: En Revista: Sci Signal Asunto de la revista: CIENCIA / FISIOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_leukemia Asunto principal: Reordenamiento Génico / Leucemia Mieloide Aguda / N-Metiltransferasa de Histona-Lisina / Proteína de la Leucemia Mieloide-Linfoide / Proteínas de la Ataxia Telangiectasia Mutada / Neoplasias Experimentales Límite: Animals / Humans Idioma: En Revista: Sci Signal Asunto de la revista: CIENCIA / FISIOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: España
...